CHRS

$0.00

(

0.00%

)
Quote details

stock

Coherus BioSciences Inc

NASDAQ | CHRS

1.70

USD

(

0.00%

)

At Close (As of Jan 1, 1970)

$201.07M

Market Cap

3.264

P/E Ratio

0.53

EPS

$2.43

52 Week High

$0.66

52 Week Low

HEALTHCARE

Sector

CHRS Chart

Recent Chart
Price Action

CHRS Technicals

Tags:

CHRS Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $149M
Total Revenue $267M
Cost Of Revenue $118M
Costof Goods And Services Sold $118M
Operating Income -$112M
Selling General And Administrative $140M
Research And Development $93M
Operating Expenses $261M
Investment Income Net -
Net Interest Income -$27M
Interest Income -
Interest Expense $27M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $5.3M
Income Before Tax $29M
Income Tax Expense $29M
Interest And Debt Expense -
Net Income From Continuing Operations $29M
Comprehensive Income Net Of Tax -
Ebit $56M
Ebitda $61M
Net Income $29M

Revenue & Profitability

Earnings Performance

CHRS Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $449M
Total Current Assets $342M
Cash And Cash Equivalents At Carrying Value $126M
Cash And Short Term Investments $126M
Inventory $70M
Current Net Receivables $122M
Total Non Current Assets $107M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets $54M
Intangible Assets Excluding Goodwill $54M
Goodwill $0
Investments -
Long Term Investments -
Short Term Investments $0
Other Current Assets $23M
Other Non Current Assets -
Total Liabilities $581M
Total Current Liabilities $283M
Current Accounts Payable $28M
Deferred Revenue -
Current Debt -
Short Term Debt $4.5M
Total Non Current Liabilities $298M
Capital Lease Obligations $5M
Long Term Debt $265M
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $270M
Other Current Liabilities $250M
Other Non Current Liabilities $28M
Total Shareholder Equity -$132M
Treasury Stock -
Retained Earnings -$1.6B
Common Stock $12K
Common Stock Shares Outstanding $115M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$20M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $5.3M
Capital Expenditures $0
Change In Receivables -
Change In Inventory -$32M
Profit Loss -
Cashflow From Investment $230M
Cashflow From Financing -$187M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income $29M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $149M
Total Revenue $267M
Cost Of Revenue $118M
Costof Goods And Services Sold $118M
Operating Income -$112M
Selling General And Administrative $140M
Research And Development $93M
Operating Expenses $261M
Investment Income Net -
Net Interest Income -$27M
Interest Income -
Interest Expense $27M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $5.3M
Income Before Tax $29M
Income Tax Expense $29M
Interest And Debt Expense -
Net Income From Continuing Operations $29M
Comprehensive Income Net Of Tax -
Ebit $56M
Ebitda $61M
Net Income $29M

CHRS News

CHRS Profile

Coherus BioSciences Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Coherus BioSciences Inc. is a leading biopharmaceutical company specializing in the development and commercialization of biosimilars and innovative immuno-oncology therapies, primarily targeting the U.S. market. Based in Redwood City, California, Coherus aims to enhance patient access to high-quality biologics while driving down healthcare costs. With a robust pipeline and strategic collaborations, the company is positioned to capitalize on the growing demand for affordable treatment options in the oncology and autoimmune disease sectors.

VHAI
+66.66%
$0.00
YYAI
-11.76%
$0.15
BURU
-20.39%
$0.40
UGRO
+54.52%
$0.57
NVDA
-4.40%
$180.03
CGBS
-39.47%
$0.03
PLUG
+6.26%
$4.14
BITF
+28.33%
$5.39
NVTS
+26.07%
$12.57
TMQ
+59.90%
$10.49
RGTI
+2.20%
$56.12
CAN
+18.42%
$1.80
DNN
+3.73%
$3.19
INTC
-4.27%
$35.63
LAES
+24.79%
$7.65
BYND
-23.22%
$0.79
JOBY
+8.05%
$18.12
RR
+4.34%
$6.73
RXRX
+6.50%
$5.89
SSKN
+41.55%
$2.18
ITP
+31.05%
$0.34
F
+1.08%
$11.66
EDHL
+114.42%
$1.07
CRML
+28.73%
$29.97
WULF
+10.42%
$15.46
ACHR
+1.91%
$13.01
BBD
+2.10%
$3.15
SOUN
+8.98%
$20.86
NAK
+4.13%
$2.76
SOFI
+2.68%
$27.87
TLRY
-5.32%
$1.60
QBTS
+5.93%
$43.03
DVLT
+24.76%
$2.12
IONZ
+11.73%
$2.57
BTBT
+3.25%
$4.13
GPUS
-6.93%
$0.40
MARA
+9.88%
$22.24
TSLA
-1.52%
$429.24
AMD
+0.77%
$218.09
AXDX
-61.36%
$0.03
CLF
+0.83%
$13.94
QS
+15.57%
$16.98
ERIC
+20.56%
$9.85
RIG
-2.65%
$3.11
ETHD
+6.45%
$3.54
CIFR
+2.70%
$20.89
NIO
-5.15%
$6.81
QUBT
+1.49%
$21.78
NUAI
+30.63%
$3.07
UAMY
+4.24%
$17.42
ASST
-7.69%
$0.99
NOK
+4.28%
$5.47
CLSK
+9.68%
$21.98
PLTR
+1.42%
$179.74
APLD
+2.33%
$35.04
IREN
+8.16%
$69.37
AREC
+36.74%
$6.81
ABAT
+36.59%
$9.22
RF
+2.40%
$25.15
BTG
+0.94%
$5.36
KDLY
-1.56%
$0.85
AAL
+1.90%
$11.74
USAR
-2.72%
$37.62
UUUU
+16.86%
$23.77
PFE
-0.82%
$24.52
BAC
+2.45%
$50.06
SNAP
-1.61%
$7.92
BMNR
-6.84%
$52.96
RMBL
+60.50%
$3.21
MP
+3.78%
$98.66
ADAP
-2.59%
$0.18
AMZN
-1.69%
$216.34
T
+2.11%
$26.13
ADD
-25.47%
$0.05
JBLU
+7.91%
$4.91
ONDS
-3.70%
$10.41
AAPL
+0.04%
$247.77
SRM
+53.27%
$10.30
ATXS
+37.07%
$11.61
AQMS
+198.89%
$29.62
HPE
+0.76%
$24.99
IONQ
-5.50%
$77.56
BCRX
-8.59%
$6.43
EOSE
-0.41%
$16.98
NAKA
-7.78%
$0.78
KDP
+2.32%
$26.42
GRAB
-0.33%
$5.91
RGTZ
-4.94%
$8.84
GWH
-15.91%
$7.61
BULL
-0.08%
$11.73
DFLI
-2.54%
$1.53
ABEV
+1.16%
$2.16
VALE
+2.41%
$11.01
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
NB
+3.09%
$11.67
WLGS
-5.57%
$0.04
GDXD
+3.16%
$0.75
FHN
+2.47%
$23.00
WWR
+29.29%
$2.56
VHAI
+66.66%
$0.00
YYAI
-11.76%
$0.15
BURU
-20.39%
$0.40
UGRO
+54.52%
$0.57
NVDA
-4.40%
$180.03
CGBS
-39.47%
$0.03
PLUG
+6.26%
$4.14
BITF
+28.33%
$5.39
NVTS
+26.07%
$12.57
TMQ
+59.90%
$10.49
RGTI
+2.20%
$56.12
CAN
+18.42%
$1.80
DNN
+3.73%
$3.19
INTC
-4.27%
$35.63
LAES
+24.79%
$7.65
BYND
-23.22%
$0.79
JOBY
+8.05%
$18.12
RR
+4.34%
$6.73
RXRX
+6.50%
$5.89
SSKN
+41.55%
$2.18
ITP
+31.05%
$0.34
F
+1.08%
$11.66
EDHL
+114.42%
$1.07
CRML
+28.73%
$29.97
WULF
+10.42%
$15.46
ACHR
+1.91%
$13.01
BBD
+2.10%
$3.15
SOUN
+8.98%
$20.86
NAK
+4.13%
$2.76
SOFI
+2.68%
$27.87
TLRY
-5.32%
$1.60
QBTS
+5.93%
$43.03
DVLT
+24.76%
$2.12
IONZ
+11.73%
$2.57
BTBT
+3.25%
$4.13
GPUS
-6.93%
$0.40
MARA
+9.88%
$22.24
TSLA
-1.52%
$429.24
AMD
+0.77%
$218.09
AXDX
-61.36%
$0.03
CLF
+0.83%
$13.94
QS
+15.57%
$16.98
ERIC
+20.56%
$9.85
RIG
-2.65%
$3.11
ETHD
+6.45%
$3.54
CIFR
+2.70%
$20.89
NIO
-5.15%
$6.81
QUBT
+1.49%
$21.78
NUAI
+30.63%
$3.07
UAMY
+4.24%
$17.42
ASST
-7.69%
$0.99
NOK
+4.28%
$5.47
CLSK
+9.68%
$21.98
PLTR
+1.42%
$179.74
APLD
+2.33%
$35.04
IREN
+8.16%
$69.37
AREC
+36.74%
$6.81
ABAT
+36.59%
$9.22
RF
+2.40%
$25.15
BTG
+0.94%
$5.36
KDLY
-1.56%
$0.85
AAL
+1.90%
$11.74
USAR
-2.72%
$37.62
UUUU
+16.86%
$23.77
PFE
-0.82%
$24.52
BAC
+2.45%
$50.06
SNAP
-1.61%
$7.92
BMNR
-6.84%
$52.96
RMBL
+60.50%
$3.21
MP
+3.78%
$98.66
ADAP
-2.59%
$0.18
AMZN
-1.69%
$216.34
T
+2.11%
$26.13
ADD
-25.47%
$0.05
JBLU
+7.91%
$4.91
ONDS
-3.70%
$10.41
AAPL
+0.04%
$247.77
SRM
+53.27%
$10.30
ATXS
+37.07%
$11.61
AQMS
+198.89%
$29.62
HPE
+0.76%
$24.99
IONQ
-5.50%
$77.56
BCRX
-8.59%
$6.43
EOSE
-0.41%
$16.98
NAKA
-7.78%
$0.78
KDP
+2.32%
$26.42
GRAB
-0.33%
$5.91
RGTZ
-4.94%
$8.84
GWH
-15.91%
$7.61
BULL
-0.08%
$11.73
DFLI
-2.54%
$1.53
ABEV
+1.16%
$2.16
VALE
+2.41%
$11.01
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
NB
+3.09%
$11.67
WLGS
-5.57%
$0.04
GDXD
+3.16%
$0.75
FHN
+2.47%
$23.00
WWR
+29.29%
$2.56

Charts powered by TradingView


Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.